These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 9526812

  • 1. Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
    Vega GL, Grundy SM.
    Am J Cardiol; 1998 Feb 26; 81(4A):36B-42B. PubMed ID: 9526812
    [Abstract] [Full Text] [Related]

  • 2. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ.
    Atherosclerosis; 2002 Sep 26; 164(1):129-45. PubMed ID: 12119202
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH.
    Am J Cardiol; 1995 Jul 13; 76(2):129A-135A. PubMed ID: 7604788
    [Abstract] [Full Text] [Related]

  • 6. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF.
    Am J Cardiol; 1995 Feb 15; 75(5):348-53. PubMed ID: 7856526
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M, Schaefer EJ, Millar JS, Jones PJ, Dolnikowski GG, Vergani C, Lichtenstein AH.
    Arterioscler Thromb Vasc Biol; 1997 Oct 15; 17(10):1910-7. PubMed ID: 9351353
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
    Zambón D, Ros E, Rodriguez-Villar C, Laguna JC, Vázquez M, Sanllehy C, Casals E, Sol JM, Hernández G.
    Metabolism; 1999 Jan 15; 48(1):47-54. PubMed ID: 9920144
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Endocrinology; 1999 Nov 15; 140(11):5293-302. PubMed ID: 10537160
    [Abstract] [Full Text] [Related]

  • 14. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, McCormick SP, Marcovina SM, Barrett PH.
    Arterioscler Thromb Vasc Biol; 2015 Dec 15; 35(12):2686-93. PubMed ID: 26515419
    [Abstract] [Full Text] [Related]

  • 15. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD, Smirnova EA, Merched A, Visvikis S, Siest G, Yakushkin VV, Tsibulsky V.
    Biochim Biophys Acta; 2000 Feb 24; 1484(1):29-40. PubMed ID: 10685028
    [Abstract] [Full Text] [Related]

  • 16. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy.
    Vega GL, Grundy SM.
    JAMA; 1990 Dec 05; 264(21):2759-63. PubMed ID: 2232062
    [Abstract] [Full Text] [Related]

  • 17. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.
    Diabetes; 2003 Mar 05; 52(3):803-11. PubMed ID: 12606523
    [Abstract] [Full Text] [Related]

  • 18. Triglyceride as a risk factor for coronary artery disease.
    Gotto AM.
    Am J Cardiol; 1998 Nov 05; 82(9A):22Q-25Q. PubMed ID: 9819100
    [Abstract] [Full Text] [Related]

  • 19. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM.
    Garg A, Grundy SM.
    Diabetes; 1989 Mar 05; 38(3):364-72. PubMed ID: 2917701
    [Abstract] [Full Text] [Related]

  • 20. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome.
    Grundy SM.
    Am J Cardiol; 1998 Feb 26; 81(4A):18B-25B. PubMed ID: 9526809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.